Comments

USITC Litigation Funding Disclosure Comments Reveal Overwhelming Public Support

Analysis of comments to Proposed § 210.14a Disclosure Rule (Real-Party-in-Interest / Third-Party Litigation Funding Disclosure in Section 337 Investigations)

Roughly 82% of the 28 unique comments submitted support the disclosure rule, with just 5 commenters, or 18%, opposed.  Those opposed comprised primarily litigation funding lobbying organizations and advocates. Most commenters, regardless of their overall position, proposed amendments or clarifications to the rule.

Comments responding to the ITC’s April 30th Notice of Proposed Rulemaking (NPRM) are accessible via the ITC’s Electronic Document Information System (EDIS). This analysis reflects comments posted on EDIS as of July 10, 2026.

On April 30, 2026, the U.S. International Trade Commission published a Notice of Proposed Rulemaking (91 Fed. Reg. 23190) to add a new § 210.14a to 19 C.F.R. Part 210, requiring parties and intervenors in Section 337 investigations to disclose (1) parent corporations/stock owners, (2) entities with the legal right to bring the investigation besides the complainant, and (3) third-party litigation funders and entities whose approval is needed for litigation/settlement decisions.

Section 337 investigations before the U.S. International Trade Commission (ITC or Commission) have become an increasingly popular venue for patent holders to enforce their rights. A Section 337 complainant who prevails can obtain an exclusion order barring the importation of infringing goods, without the multi-year timelines often associated with parallel district court litigation—and without the need to prove damages. As the volume and profile of Section 337 investigations has grown, so has the role that third-party litigation funders play in bringing those cases. Until now, however, the Commission's rules have not required complainants to disclose whether an outside funder has a financial interest in, or exercises control over, an investigation.

The prevalence of third-party funding in patent litigation is well documented elsewhere. In a December 2024 report, the U.S. Government Accountability Office found that third-party litigation funding now accounts for a substantial share of all patent litigation, and that most large technology companies surveyed reported that more than half of the patent suits filed against them involved confirmed or suspected third-party funding. Federal district courts have already begun responding to this trend: Chief Judge Colm Connolly of the District of Delaware, for instance, issued a standing order in April 2022 requiring parties before him to disclose litigation funding arrangements. Congress has introduced a series of bills aimed at the same problem—including the End Anonymous Patents Act (2013, 2015), the Litigation Transparency Act (2024), and, most recently, the narrower Litigation Funding Act of 2026 (introduced in February 2026)—though none has yet been enacted.

The ITC's proposal follows a direct legislative request. In a September 2025 report accompanying its appropriations bill, the House Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies urged the Commission to “promptly implement measures to ensure disclosure of any persons and entities with a beneficial interest” in Section 337 investigations. On April 30, 2026, the Commission answered that call, publishing a Notice of Proposed Rulemaking that would amend 19 C.F.R. Part 210 to require complainants—and potentially other non-government parties—to file a disclosure statement, concurrent with the complaint, identifying their parent corporation, any entity with an ownership interest in the complainant, and any entity that provides funding for the investigation or whose approval is required for litigation or settlement decisions.

The Commission has offered three justifications for the proposed rule: facilitating conflict-of-interest screening for Commissioners, Administrative Law Judges, and Commission staff; providing early clarity about which entities' rights are genuinely at issue in an investigation; and promoting transparency to facilitate settlement. Notably, the proposal as drafted would require only identification of interested entities, not production of the underlying funding agreements themselves. The Commission specifically invited comment on several open questions, including whether any ownership-disclosure obligation should be triggered only above a particular ownership percentage, and whether the disclosure obligation should extend to all parties or be limited to complainants.

The proposal arrives amid a broader, bipartisan push for transparency around litigation funding across the federal government. In March 2026, the U.S. Chamber Institute for Legal Reform and Lawyers for Civil Justice jointly proposed amending Federal Rule of Civil Procedure 26 to require automatic disclosure of third-party litigation funding, and in February 2026, Senator Chuck Grassley introduced the Litigation Funding Act of 2026. As with the USPTO's recent rulemakings affecting the Patent Trial and Appeal Board, the ITC's proposal drew a robust public response over its comment period.

As of July 10, 2026, roughly 22 out of the 28 distinct commenters support the rule–with most urging that the rule be made broader and harder to evade.  Those supporters include the major bar associations, US companies, trade associations, and economic empowerment groups. 

4 opposed it outright (ILFA, IDA, ACAA, Lone), while NPE Daedalus Prime’s comments were mixed, in that it opposed mandatory funder-identity disclosure, but supported approval-rights disclosure. 

The many supporters of the disclosure rule include numerous American operating companies, tech/hardware trade associations, and business-litigation reform groups, while opponents are unsurprisingly members of the litigation-funding industry itself as well as inventor and justice accessibility advocacy groups.

Of the 28 comments, 25 propose at least one specific, concrete rule-text change; 3 (Save Our Standards, American Civil Accountability Alliance, and — largely — Inventors Defense Alliance) confine themselves to general support or opposition without proposing alternative text. The most common proposal, appearing in roughly 20 of 28 letters across both supporters and opponents of the broader NPRM, is adoption of a 10% ownership-disclosure threshold modeled on FRCP 7.1. Several other proposals—closing the "counsel loophole," broadening the funding trigger beyond the specific ITC matter, and adding a continuing duty to update disclosures—also draw support from a dozen or more commenters.

Support for the Rule

A vast majority of the commenters (22 out of 28) support the rule, citing the need for increased transparency.

Supporting the need for the rule (SIIA):

"[I]n any given Section 337 investigation, the Commission and the responding parties frequently have no way of knowing whether an undisclosed funder is directing the litigation, who that funder is, or what interests it is advancing. The proposed rule is a direct and proportionate response to that information gap."

Supporting the need for the rule (BSA): 

argues the convergence of non-practicing-entity litigation and undisclosed funding "erodes the integrity of the remedy from the inside out," depriving the Commission of "information that is foundational to evaluating whether the proceeding serves the statutory purposes that justify the remedy."

Opposing the rule (IDA):

"The proposal extends beyond traditional federal disclosure frameworks, would require disclosure of remote, passive, and immaterial interests with little relevance to the Commission's stated objectives."

Ownership Disclosure Threshold — § 210.14a(a)(1)

The single most common recommendation across supportive comments (20 out of 28) was to add a 10% ownership threshold (mirroring FRCP 7.1) rather than requiring disclosure of every entity owning any amount of stock, which, as noted by ITCTLA has been successfully used by the federal courts for more than 20 years. 

Unified Patents: argues the 10% baseline was appropriate for ordinary equity, but that a catch-all should exist for non-stock financial interests and proposes adding, after the stock-ownership language, disclosure of "any entity, other than a publicly traded company with no ownership interest above 10%, that has a direct financial interest in the outcome of this investigation, including by virtue of a profit-sharing arrangement, a right to proceeds from settlement or award, a contractual interest in licensing revenue..." to align with FRCP 7.1.

ABA: also recommends aligning with FRCP 7.1, “requiring identification of ‘any parent corporation and any publicly held corporation owning 10% or more of its stock,’” which would “reduce the potential burden of disclosure on parties with complex corporate structures.”

HPE/Juniper: explains the practical burden on public companies:

"HPE has thousands of shareholders that are not necessarily known to the company and can change frequently, rendering it impracticable for HPE—or any publicly-traded company for that matter—to comply with the proposed rule in the absence of an ownership threshold."

IDA (opposing broad disclosure generally): argues the absence of a threshold is the core flaw:

"The rule could be read to seek the identity of each and every individual in an investment vehicle, such as a pensioner member of a pension fund."

The "Funding Specifically for the Investigation" Loophole — § 210.14a(a)(3)(i)

This was the most frequently criticized piece of drafting among supportive commenters (13 comments; 3 limiting/opposing), who warned that funders finance multi-forum "campaigns" or "portfolios" rather than single ITC proceedings, allowing the funding trigger to be circumvented. Indeed, funded lobbying entities already assume that campaign portfolio funding would be excluded as written. 

TechNet, citing a real example:

"Atlantic IP and its subsidiary Arigna Technologies Ltd., both Irish entities, have pursued a worldwide patent campaign and filed Section 337 actions at the Commission against U.S. businesses including Apple, Google, General Motors, and Microsoft. We recommend that the Commission instead require disclosure of any entity that stands to benefit, financially or otherwise, from any agreement that contemplates the outcome of the investigation."

SIIA proposed changes to the rule text: 

"That provides funding for, or that has a financial interest in the outcome of, the section 337 investigation, whether pursuant to an agreement relating specifically to the section 337 investigation or to an agreement covering related litigation in any other forum..."

Apple proposed nearly identical language and framed the fix as a functional test: "The touchstone should be whether a non-party has a meaningful stake in the outcome or meaningful influence over the investigation—not whether its role fits within a narrow corporate label."

HTIA recommended adjusting the language to funding "for a patent assertion campaign" rather than "specifically for the section 337 investigation."  Directionally, that would include, inter alia, portfolio funding, and include trade secret, trademark, and unfair competition claims.

Contrasting industry view (ILFA): ILFA — representing litigation funders — argued that the language as proposed already excludes portfolio funding, seemingly in anticipation of counselling its members not to disclose such funding:

"This additional language makes clear that law firm portfolio funding arrangements are excluded... The funder is not in contractual privity with the underlying litigant, and the lawyers are subject to the Rules of Professional Conduct. The funder accordingly has no ability to control or influence the litigation."

The Counsel Exclusion / Law-Firm-Financing Loophole — § 210.14a(a)(3)

One of the most frequently proposed amendments (12 supporting; 1 opposing) was to require disclosure when a funder finances a party’s outside counsel or law firm’s case portfolio directly, rather than the party itself, which allows the funder to avoid disclosure entirely. The ILFA comments suggest that funding entities are already preparing to exclude such arrangements from disclosure compliance as written. 

Garmin flagged this specifically:

"Many litigation financiers in the United States now directly fund law firms through loans, revolving lines of credit, nebulous financial instruments, or by purchasing interests in shares of the firm's cases... The complexity of these financial arrangements should not be a reason to evade disclosure under the proposed transparency rules."

HTIA, from direct litigation experience:

"In many cases that HTIA encounters, the lawyers supposedly representing a complainant or plaintiff are the only real party in interest in the case. The named plaintiff is often a nominal party; it is the lawyers themselves who are controlling the case and who will principally benefit from any award or settlement."

Unified Patents' noted that the "Proven Networks" case study illustrates this issue. Unified describes an ITC complainant (Proven Networks LLC, Inv. Nos. 337-TA-1275 and 337-TA-1306) that was originally formed as an LLC by attorneys from the Russ August & Kabat firm, who were listed as members/managers, with the business purpose of "investment in patent portfolio":

"[T]he complainant in that investigation was an entity created and controlled by its own litigation counsel, whose financial returns depended entirely on the success of the very litigation they were conducting... Counsel here are not merely being paid a contingency fee; they are equity investors in the complainant entity whose entire financial return depends on the outcome of the investigation."

Unified's recommended fix would carve law-firm equity stakes and firm-level funder financing back into the disclosure requirement, limiting the counsel exclusion to "standard contingency fee arrangements."

Apple proposed narrowing language (with SIIA proposing nearly identical language as well) limiting the counsel exclusion to counsel acting "solely in their capacity as legal counsel under a ... bona fide attorney-client engagement or contingency-fee arrangement entered into in the ordinary course."

Should the Underlying Funding Agreement Be Produced?

One of the sharpest splits across the commenters: identity-only disclosure vs. production of the actual contract.

Require production of the agreement (ILR, CCIA, Intel, BSA, CTA): 

ILR

"Experience has demonstrated that summary descriptions of funding arrangements often prove insufficient to identify governance rights, veto rights, waterfall provisions, repayment structures, or other provisions that may materially affect litigation conduct. Production of the agreement allows the Commission to evaluate the actual rights created by the arrangement rather than relying on party characterizations."

BSA

"The only way to evaluate whether a funding arrangement presents the kind of influence risk that the Commission's rule is designed to address is to examine the actual agreement."

Identity/description only — no agreement production: 

ILFA:

"The Proposed Rule reflects the considered judgment of the Commission about what level of disclosure is appropriately tailored to achieve legitimate transparency goals. It requires limited disclosure regarding a capital provider's identity and rights. It does not require the production of funding agreements... Most federal courts to consider the question have found that funding agreements constitute protected attorney work product."

Daedalus Prime, opposing the funder-identity disclosure requirement in general, made a related "no benefit" argument specifically about respondents gaining unfair strategic insight:

"If there is a litigation funder, then the opposing side will now know more information regarding the complainant's funding for which respondents may use to their advantage. And if there is no litigation funder... that information, too, disproportionately provides the respondents with a strategic benefit... no matter what the situation, the disclosure requirement will... provide an imbalanced strategic advantage to the respondents."

Related/Parallel Litigation Funding Disclosure

The NPRM specifically asked whether funding or approval rights in related litigation (parallel district court cases, PTAB, foreign proceedings) should also be disclosed.

Yes, extend to related litigation (ITCMA, HPE, TechNet, R Street, Unified Patents, ILR): 

ILR

"ITC proceedings frequently arise in the context of broader civil litigation, and without knowledge of funding arrangements in those parallel proceedings, neither the ITC nor the parties can obtain a complete and accurate picture of the interests and incentives driving the dispute."

Unified Patents

"The funder who is financing the ITC proceeding is virtually always financing the parallel proceedings as well... Prior agreements between a funder... and a respondent may prohibit the litigation. Those prior agreements can only be identified if the respondent knows who the funder is."

No, keep the rule ITC-specific (ITCTLA, AAI, Doane): 

ITCTLA: "The ITCTLA does not view funding or necessary approval information from related litigation as relevant to most Section 337 investigations," preferring to let ALJs decide case-by-case based on "specific facts and contentions."

AAI

"The Commission should decline to extend proposed § 210.14a(a)(3)(i) and (ii) to funding or approvals in related litigation outside of the ITC. Such an extension would broaden the rule beyond its stated purpose and create unnecessary parallel-proceeding complications."

National Security / Foreign Funding

A large share of supportive comments emphasized foreign-funder opacity as a national-security rationale, often citing the same handful of examples.

TechNet: 

"Anonymous funding — whether sourced from foreign sovereign wealth funds, opaque private equity vehicles, or entities with undisclosed ties to foreign adversaries — can be used to target specific U.S. and allied manufacturing nodes... Without disclosure, the Commission cannot reliably distinguish a legitimate Section 337 complaint from a tool of foreign economic disruption."

BSA: documents that "[f]rom 2021 to 2023, four of the top five NPEs were based outside the US or ultimately owned by non-US persons.”

HTIA, with a detailed example: 

"HTIA member company Google has been sued more than 50 times by Uniloc, which is a PAE associated with (and funded by) the Fortress Investment Group... Fortress is controlled by Mubadala Investment Company, a state-owned investment management holding company that acts as one of the sovereign wealth funds of the Emirate of Abu Dhabi." 

HTIA also recounts VLSI Technology's (Fortress-backed) decision to abandon a $3 billion suit against Intel and grant a covenant not to sue rather than comply with Delaware Chief Judge Connolly's funder-disclosure order.

ILR compiled an extensive record on this point, including letters from Senators Kennedy, Cornyn, Tillis, Scott, and Rubio, a House Select Committee on the CCP report, and the Purplevine IP (China)/Samsung and VLSI/Fortress/Mubadala examples, along with a warning from a DOJ FARA Unit official that undisclosed foreign funding creates three risks: competitive-disadvantage litigation campaigns, discovery-enabled access to sensitive information, and funding of divisive political litigation.

(No commenter argued affirmatively against the foreign-influence rationale; opponents of the rule instead argued the existing domestic-industry requirement and Commission authority to request additional information already address this risk — see ACAA, Section 1 above.)

Access to Justice / Small Business & Independent Inventor Concerns

This is the core of the opposition case, made most fully by Doane, IDA, ACAA, and (in part) Daedalus Prime.

IDA:

"Strong intellectual property rights are meaningful only if innovators have the ability to enforce them... Restricting access to capital does not disadvantage [large, well-resourced foreign infringers]. It disadvantages the American innovators attempting to stop them."

Daedalus Prime, a licensing company and active ITC complainant, framed disclosure as tilting leverage toward well-resourced respondents:

"Litigation financing corrects this imbalance, helping to foster license agreements and outcomes that reflect the true merits of the dispute rather than disparities in the parties' resources." 

Daedalus also cites the legislative history of the 1988 Section 337 amendments (Sen. Lautenberg) emphasizing that "[s]maller businesses should not be denied the right to seek relief merely because they may have made smaller financial investments... in developing or exploiting an intellectual property right."

Counterpoint — small-business trade associations that still support disclosure (ACT, CTA): Notably, ACT and CTA — both small-business/startup-focused associations — took the opposite view, arguing that opaque funded patent assertion actually harms their small-business members as targets. 

ACT

"Small businesses that drive American technological leadership and job creation are frequent targets of abusive patent litigation, including litigation funded by undisclosed third parties.”

However, ACT noted that even though TPLF can be a valuable tool, transparency is essential. 

Continuing Duty to Supplement Disclosures

There was broad support among pro-disclosure commenters (10 comments) for adding an ongoing supplementation obligation (the NPRM as drafted only requires disclosure at filing). As HTIA notes, "it is not uncommon for third-party litigation funders to begin to finance a litigation or investigation after the proceeding has commenced."

  • Intel, ITCMA, SIA, R Street, ACT, CCIA, HTIA, Unified Patents, Apple, Ravnitzky all recommend a supplementation duty, most citing FRCP 7.1(b)(2)'s "promptly file a supplemental statement if any required information changes" as the model.

  • The proposed timeframes vary: 10 days (Intel, ITCMA, Apple), 14 days (Unified Patents), 30 days (Ravnitzky), or simply "promptly" (ACT, following FRCP 7.1(b)(2) directly).

Enforcement / Sanctions for Non-Compliance

Several commenters noted the NPRM is silent on consequences for non-disclosure or false disclosure and proposed adding teeth to the disclosure obligation (7 comments), such as adverse inferences, evidentiary limits, fee-shifting, or dismissal for false or withheld disclosures.

Several commenters flagged that the proposed rule's language invites willful blindness, and recommended a certification requirement after "reasonable inquiry," similar to FRCP 11.

ITCMA and SIA: both recommend the Commission have "explicit authority to compel supplementation and impose sanctions for nondisclosure, including evidentiary limitations, fee shifting, adverse inferences, protective-order restrictions, or dismissal in egregious cases."

Unified Patents: proposes that "willful failure to comply... may be sanctioned by the Administrative Law Judge including by adverse inference, exclusion of evidence, or dismissal of a complaint or defense."

Public Filing vs. Confidential Treatment

Several commenters suggest public filing of at least identity information be required (SIIA, ACT, Apple). For example, SIIA said that "[w]ithout [a public-filing requirement], a party could seek confidential treatment of the funder's identity under 19 C.F.R. § 201.6, which would undermine the very transparency the rule is meant to create." SIIA and Apple both propose identical rule text requiring public filing of identity/address/place of formation while allowing confidential treatment only of the specific commercial terms of funding/approval arrangements.

Others argued that the rule allows confidential treatment of sensitive commercial terms (SEMI, ITCTLA) SEMI recommends the Commission "confirm that disclosure statements containing such information may be filed confidentially in accordance with the Commission's existing rules governing confidential business information... with a public version identifying the covered entities."

Who Must Disclose? Complainants Only or All Parties?

The ABA and AAI support the provision applying to complainants only.

ABA: "The Section believes this provision is most naturally directed at complainants, as the concept of having the 'legal right to bring' the investigation is one that arises on the complainant side."

AAI: "There is no apparent purpose to requiring disclosures for intervenors and respondents—a respondent who is found to infringe, for example, is subject to an exclusion order regardless of what relationship it has with other entities."

ITCMA, R Street, ACT, SIA in part argued that it should apply to all parties:

R Street: "The rationale for the proposed rule applies equally to all parties in an investigation; a one-sided disclosure rule provides only asymmetric information that would not fully inform the Commission."

ACT: supports disclosure by "complainants, respondents, and intervenors," reasoning that "[k]nowing the real parties in interest and those controlling the litigation will aid parties, the Commission, and the public in determining whether there are any public interest concerns."


Prepared from the 34 PDFs uploaded to EDIS under ITC Docket No. MISC-051 (comment period closing June 29, 2026). Two Federal Register notices and one internal "Action Jacket Approval Record" were procedural documents, not public comments, and are not analyzed above. Three commenters (ILR, SOS, ACT) and one (HTIA) each appear to have filed duplicate copies of the same letter under two docket entries; these are treated as single comments above.

Why the ITC’s Litigation Funding Disclosure Proposal Is Good Policy — and Why It Needs Sharper Teeth

In April 2026, the U.S. International Trade Commission published a Notice of Proposed Rulemaking (91 Fed. Reg. 23190) to add a new § 210.14a to 19 C.F.R. Part 210, requiring parties and intervenors in Section 337 investigations to disclose (1) parent corporations/stock owners, (2) entities with the legal right to bring the investigation besides the complainant, and (3) third-party litigation funders and entities whose approval is needed for litigation/settlement decisions. Comments closed on the docket (MISC-051) in June, and Unified Patents filed comments strongly supporting the rule, while urging the Commission to close several loopholes before finalizing it.

ITC remedies are unusually powerful, which makes them unusually attractive to funders. A Section 337 exclusion order can block an entire product category from the U.S. market — a form of leverage far more immediate and severe than a district court damages award. That leverage translates directly into licensing revenue for whoever is bankrolling the case, regardless of whether the underlying patents have merit. Compressed eighteen-month timelines, no damages cap, a domestic industry test that can be satisfied by a single licensee, and the absence of fee-shifting for prevailing respondents all combine to make the ITC an appealing venue for investors who never intend to practice the patents they’re asserting.

Right now, those investors can stay completely invisible. Commissioners, administrative law judges, and Commission staff currently have no systematic way to know whether a hidden funder — including a foreign entity with no accountability to U.S. policy objectives — is directing the litigation. Respondents can’t tell whether a prior agreement with that funder should have barred the case in the first place, and the Commission can’t properly screen for conflicts of interest.

Disclosure of this kind isn’t a novel or radical idea. It brings the ITC in line with rules already in place in federal courts, including the Northern District of California and the District of Delaware, and with the direction the Federal Rules Advisory Committee is heading more broadly. And disclosure lets the Commission screen for conflicts, lets respondents evaluate whether prior agreements bar a case, and lets everyone involved understand who actually stands to profit from an exclusion order.

This increased transparency is why Unified supports the proposed rule. Our comment also recommends closing the loopholes for portfolio-level funding, attorney-investor structures, parent-subsidiary arrangements, and controlling individuals who currently fall outside the disclosure requirement, along with adding an ongoing disclosure obligation and real consequences for noncompliance.


Unified Patents is a membership-based organization that works to deter unmeritorious patent assertions across the automotive, cloud computing, consumer electronics, fintech, media, semiconductor, and related industries.

Comments submitted to the USPTO over AI impacts on prior art

Through policy advocacy work with Unified Edge, Unified Patents has submitted comments to the USPTO's request for comments regarding the impact of the proliferation of artificial intelligence (AI) on prior art, the knowledge of a person having ordinary skill in the art, and determinations of patentability made in view of the foregoing.

Unified has suggested that the USPTO may need to be wary of unscrupulous actors creating AI data dumps, including using bulk patent applications at the USPTO itself to create patent thickets.

Read through Unified’s comments by clicking on the button below:

Comments to the USPTO submitted regarding terminal disclaimer practice

Through policy advocacy work with Unified Edge, Unified Patents has submitted comments to the USPTO's recent NPRM regarding conditions for obtaining terminal disclaimers to obviate obviousness-type double patenting.

In 2022, the USPTO requested comments regarding USPTO Initiatives to Ensure the Robustness and Reliability of Patent Rights. The Office has proposed a rule that would cut down on examiner wear-down and the abusive assertions of obvious variations of continuation patents through current terminal disclaimer practice. Unified has written to support the proposed rule.

Read through Unified’s comments by clicking on the button below:

The Public Has Spoken: Stakeholders Overwhelmingly Oppose Proposed Restrictions on Patent Trial and Appeal Board Review

Public comments responding to U.S. Patent and Trademark Office proposals have been posted on regulations.gov on a rolling basis. This analysis has been updated from the original version – July 23, 2023 – to reflect comments posted on regulations.gov as of August 22, 2023.

Before Congress in April, Director Vidal testified that the U.S. Patent and Trademark Office’s (USPTO) recent Advance Notice of Proposed Rulemaking (ANPRM) on the Patent Trial and Appeal Board “contains a myriad of options, and we want to hear from stakeholders not only on how those provisions might affect them, how we should evolve them, but whether we even have the authority to move forward with them.” And boy, did the public respond. The Office heard from more than 14,500 comments, the most on record for any administrative patent-related action in the USPTO’s long history.

The response was overwhelming, broad-based opposition to the ANPRM’s proposals. More than 95% of all public comments—and nearly 85% of unique comments—opposed the proposals, according to analysis by Unified Patents. 

It should not be surprising that stakeholders oppose the ANPRM. New economic analysis found that over the next 10 years the proposals would result in a net decrease in U.S. business activity of -$482.1 million in gross product, a net decrease of -$230.4 million in personal income, a net decrease of -2,000 job-years of employment, and $202.9 million in additional costs to the federal government – between lost tax receipts and higher procurement costs.

As the comments emphasize, proposals that make it more difficult to challenge invalid patents—including new standing requirements for petitioners—would be a drag on the economy, slow innovation, and burden productive businesses with increased costs. The ANPRM feedback shows, rather, that stakeholders would like for the Patent Trial and Appeal Board (PTAB) to be a more accessible, more efficient alternative to litigation, as was provided for in the America Invents Act of 2011. Despite lobbying efforts to the contrary, the record is clear—the ANPRM was wrong-footed, could raise drug prices, would serve to embolden NPEs, and would be a drain on the productive American economy. 

Indeed, Director Vidal has repeatedly emphasized the importance of stakeholder input throughout her tenure; the USPTO now needs to seriously grapple with the public’s concerns, and must question whether to proceed with any rulemaking process that does not roll back ill-advised moves like the NHK-Fintiv and Valve rules, unpopular moves that have only served to limit objective review and the public’s right to petition the government. 

And the USPTO isn’t the only governing body that must heed this clarion call against these motivated “reform” efforts. Just days after the ANPRM’s comment window closed, Senator Thom Tillis (R-NC) and Senator Chris Coons (D-DE), ignoring the clamor, introduced the Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act, a rebranding of the perennial go-nowhere “STRONGER” Act that would institute many of the same unpopular changes included in the ANPRM. 

It would be undemocratic for the USPTO or Congress to justify proceeding with new restrictions for PTAB review on the heels of such a significant and decisive public outcry from stakeholders across a diverse array of sectors and with a wide range of backgrounds. It would serve special interests over a documented and overwhelming opposition; it would raise drug prices, embolden patent trolls, and prevent the USPTO from correcting its own mistakes. And the PTO likely doesn’t have the authority to make good on most of their proposals. In short: it’s bad policy. 

Recurring themes from the thousands of public comments in opposition to the changes are summarized below, and clearly demonstrate the problem with either the USPTO or particular Congressmen proposing them.

Patent Trolls are a Major Concern

The need to protect businesses of all sizes against predatory NPE or patent troll lawsuits is a consistent theme across a majority of the comments. The term “patent troll,” “NPE,” or “non-practicing entities” appears in over 10,500 submissions (more than 73% of all comments), with the overarching concern that, on balance, the proposed changes to PTAB review would benefit patent trolls at the expense of economic growth and innovation. 

Congress originally established the PTAB, in part, as a response to the widely-recognized pattern of abusive patent litigation. Any changes that add new procedural hurdles will leave businesses more vulnerable to costly, bad-faith patent infringement assertions. Public input expressing concern about the new changes further enabling patent trolls includes:

  • “...Over the past few decades, businesses like hotels, restaurants, and retailers have found themselves the target of lawsuits from non-practicing entities (NPEs), sometimes called patent trolls. These NPEs will threaten businesses with claims of patent infringement on vague old patents, which frankly never should have been issued in the first place. The trolls know they have no case, but they’re relying on businesses to make the calculation that it’s cheaper to settle out of court than wage an expensive (even if successful) legal battle.

    IPR is a tool in businesses’ arsenal when it comes to defending against trolls. The program, which was created as part of the 2011 America Invents Act (AIA) allows anyone to file a challenge on an old patent to have it reviewed by the PTAB. Evidence from the first decade of the program shows that it works – 40 percent of patents challenged via IPR are ruled invalid, demonstrating that there is a robust need for a post grant review process at the PTAB.

    Unfortunately, the recent ANPRM threatens to significantly weaken the IPR process, putting businesses like our members at risk. The proposed rules would make changes to a variety of elements of the IPR process, including who can file an IPR, how long they have to file it, and what the standard for instituting an IPR is. All of these proposed changes create uncertainty for small businesses across the county, many of whom now have to worry about emboldened trolls coming after them.” – I. Diaz, Tweedy Mile Association (Nonprofit organization focused on the downtown revitalization of the city of South Gate in Los Angeles County)

  • “...NPEs and PAEs (so called ‘patent trolls’) justify their practices by claiming to be the champion of the small, independent rights-holder. They claim that they give rights-holders the ability to assert their IP against large entities that would otherwise be able to violate at-will, relying on fixed cost staff attorneys and lengthy, costly litigation. 

    I don't dispute these claims. NPEs and PAEs can serve an important function.

    The IPR process, however, has proven to be a successful counterbalance to the incentives that have driven some of these companies into unethical territory and damaged the ability of US companies to innovate and compete.

    It would be a mistake to eliminate or reduce the effectiveness of the IPR. 

    We should be moving in the other direction and expanding this program, which has a decade of proven success.” – Ratio Software, LLC (Software design and development company)

  • “...From COVID precautions, to supply chain issues, to rising inflation rates, to chronic labor shortages, our members have overcome tough odds to continue to provide goods and services to the people of the Granite State. At a time when some of our members are just beginning to see the light at the end of the tunnel, weakening the IPR process will signal to non-practicing entities (NPEs, sometimes known as “patent trolls”) that it is open season on small businesses.

    As you know, there are some bad actors out there who want to abuse the patent system – buying up old, vague patents from the earliest days of the internet, and using them to threaten or sue small businesses for alleged “infringement.” While most of these cases would easily fail in a real legal challenge, for small businesses it is significantly less expensive to settle out of court with a troll than it would be to go through an expensive trial. NPEs count on this, and can use the same old patent to extort thousands and thousands of dollars from retailers and other Main Street companies.” – NH Retail Association (Association representing more than 700 New Hampshire retailers)

PTAB Standing Requirements Would Harm Small- and Medium-sized Entities (SMEs)

Related to the more general patent trolling concern, many comments specifically raised objections to proposals in the ANPRM that would add new standing requirements for who is allowed to petition for PTAB review. More than 1,500 comments contain the specific phrase “standing requirement” and there are many additional comments that describe the same concept in different ways. Similar standing requirement measures are included in the PREVAIL Act, which would limit review to those who have been sued or are threatened with lawsuits. 

New standing requirements would remove the option of petitioning for PTAB review in many situations where a party has a legitimate interest in challenging an invalid patent. In particular, standing requirements seem to target third parties, like Unified Patents, the Texas Association of Realtors, I-MAK, or the Electronic Frontier Foundation, entities that deter abuse by challenging invalid patents. Third-party organizations are oftentimes uniquely positioned to constrain the most abusive patent troll campaigns and protect SMEs, which are most vulnerable to exploitation. 

The USPTO and Congress have both expressed a desire to make changes that serve the best interests of SMEs, small inventors, and under-resourced entities. As the public comments make clear, any new standing requirements that restrict access to the PTAB would have the opposite effect. 

The following comments emphasize the threat that standing requirements pose to SMEs: 

  • “...As you likely know, patent trolls base their business off of purchasing old patents and using them to attack small businesses for alleged “infringement” for things as simple as using a scanner. While these baseless claims have no legal standing, small businesses like mine often end up having to negotiate settlement terms with patent trolls out of court because we cannot afford to fight a prolonged battle in court… 

    …As patent troll cases have continued to rise over the years, federal lawmakers looked to take action against them by enacting the Leahy-Smith America Invents Act (AIA) in 2011. This initiated the Inter Partes Review (IPR) process, which has been pivotal for small businesses to help fight back against frivolous patent infringement cases. Because the AIA did not include a “standing” requirement to file an IPR, larger companies have also been able to file IPRs on patents being used to sue their smaller clients. 

    However, I fear that the recently introduced USPTO rules would seek to undermine IPR. Specifically, the agency has proposed allowing for less time to file an IPR, changing who can file an IPR, and rewriting the standard for instituting a review from “reasonable likelihood” to “compelling merits.” Not only would these changes directly oppose the purpose of the AIA and overstep Congress, but also empower patent trolls to expand their aggressive attacks against businesses like my own…” – M. Feldman, Roof Off Entertainment (Entertainment booking company)

  • “...The restriction on IPR challenges by nonmarket competitors will eliminate an important pathway for invalidating patents asserted against Main Street companies in NPE hold-up campaigns. Despite Congress’s considered decision that patent quality and integrity would be best served by allowing any member of the public to file an IPR, the proposed rules seek to limit who can file a petition. This will be especially injurious to UFPR’s Main Street members and companies like them who have benefited greatly from IPRs brought by others, including trade associations, patent-challenge organizations, and public interest groups. There are many examples of sweeping campaigns by NPEs seeking hold-up nuisance settlements based on invalid patents being stopped by IPR challenges brought by the types of organizations this proposal seeks to derail…” – United for Patent Reform (Business coalition representing over 90 million U.S. employees)

  • “...These petitioning organizations, including Unified Patents and Askeladden, overcome a collective action problem that bedevils patent litigation: when the plaintiff offers to settle for an amount far below the high cost of litigation, no defendant has an incentive to challenge the patent. Some patent assertion entities have filed lawsuits on the same patent over a hundred times—often targeting small business, which are even more likely to settle—before the patent’s claims were finally canceled in a challenge brought by a petitioning organization. If these organizations were prevented from operating, as the ANPRM proposes, these same assertion campaigns would no doubt have continued, repeatedly extracting small but substantial amounts from small businesses and other operating companies based on a patent that never should have issued…” – U.S. Manufacturers Association for Development and Enterprise (Nonprofit association representing companies manufacturing diverse goods in the United States)

The Open-source Community Weighed In Heavily

More than 500 comments referenced “open source” or “open-source,” almost all of which  highlighted the extent to which the proposed changes to post-grant would harm open-source software development. Software patents are a frequent point of contention in subject matter eligibility conversations, since it is an area ripe for overly-broad, abstract patents. This also means that low-quality software patents are valuable tools for patent trolls. Open-source developers and those that use their products are prime targets. 

Comments submitted by the open-source community highlight the need for accessible PTAB review in order to promote new, accessible software innovation:

  • “...Open source projects and their maintainers are uniquely vulnerable to attack by hostile parties such as patent trolls (sometimes called “non-practicing entities”) and companies rent-seeking over so-called standard-essential patents. The projects and their non-profit fiduciary hosts are not of a scale to be able to manage the usual defenses of large corporations, while the individuals themselves may seem worthwhile targets for avaricious litigators. When a project faces a patent attack, it is thus frequently defended by others as a matter of civic duty.

    The rule changes that the Patent and Trademark Office propose would greatly limit the ability of open source projects to be defended by these third parties. This would both chill the innovation and progress arising from open source software - which contributes billions to GDP - as well as embolden malicious litigators seeking reward where they have no claim simply because their victim is unable to defend themselves…” – Open Source Initiative (Public charity advocating for and enabling the benefits of Open Source)

  • “I am from the Linux Foundation and I support the collaborative development of software under free and open source licenses. A sad reality is that non-practicing entities (NPEs) have been targeting users of open source software and open source foundations with patent litigation…

    …I am deeply concerned about the impact of the proposed changes on the open source software community that relies on third-party entities to protect the openly developed commons of technology that we are all dependent upon. There are seemingly political motivations at play here. The ANPRM's proposed expansion of discretionary denials and de facto standing requirements will leave invalid patents in force to be asserted in litigation against open source foundations and companies like ours.” – J. Bonner, Linux Foundation (Linux Foundation provides a neutral, trusted hub for developers to code, manage, and scale open technology projects.)

  • “Nearly all of the rules you proposed will make it harder to challenge poor-quality patents. If implemented, these rules will make it harder to defend open source software against bad patents in the hands of patent trolls. OSS is a pillar of the entire US tech economy, and misguided intellectual property rules like this will hurt growth in the US economy as a whole.” – Gluu Inc. (Gluu curates and commercializes a distribution of the world’s best open-source digital identity infrastructure projects)

Pharmaceutical, Health Tech, and Other Health Care Organizations Spoke out in Opposition

A number of organizations in the pharmaceutical and health industries submitted comments in opposition to the substance of the ANPRM proposals, including Mylan Pharmaceuticals, Fresenius Kabi, Association for Accessible Medicines, Edwards Lifesciences, I-MAK, and Generation Patient.

A core theme in these comments is that weak patents are frequently used to delay medical progress and competition – increasing costs for patients and reducing access to potentially life-saving medicines and technologies. These organizations all align on the importance of protecting existing PTAB processes, so that PTAB review can continue being used as a tool to challenge questionable patents and therefore promote medical innovation.

  • “...In the life sciences industry, weak patents that do not actually claim a novel, innovative invention, can nonetheless delay generic or biosimilar competition for many years. To combat those delays, Mylan has filed well over 100 inter partes reviews (“IPRs”), taking advantage of Patent Trial and Appeal Board’s (“PTAB”) efficient and streamlined process to challenge weak patents that would otherwise delay patient access to life-saving medicines. Those patent challenges have allowed patients to benefit from earlier access to competition for more than $35 billion in annual brand costs…” – Mylan Pharmaceuticals (A global healthcare company that provides critical access to quality lifesaving medicines)

  • “...Inter partes review (“IPR”) and post grant review (“PGR”) each play a critical role in tackling the root cause of inappropriate delays to low-cost competition in the pharmaceutical industry. Fresenius Kabi opposes the proposed ANPRM modifications because they would so significantly undermine such challenges as to actively discourage them. By extension, the ANPRM as currently proposed would delay access to more affordable generics and biosimilars. As a general matter, unfettered access to the PTAB is particularly important in the generic drug and biosimilar industries. Each generic or biosimilar manufacturer should be free to make its best invalidity case to the Office and not risk forfeiting its right to meaningful PTAB review or other remedies available under current law…” – Fresenius Kabi (Specializes in bringing affordable, off-patent medicines to patients with critical and chronic conditions)

  • “...When it is more difficult to challenge patents, especially in the pharmaceutical field, there is more potential harm to Americans when it comes to their ability to access lower cost generics/biosimilars. This leads to an overall impact on the health of Americans and the economy….” – I-Mak (Nonpartisan, not-for-profit, and non-governmental organization working to address structural inequities in how medicines are developed and distributed)

  • “...By creating heightened barriers, these rules stifle competition and unjustifiably drive up prices, particularly for crucial medical treatments we rely on as patients. Moreover, inter partes review fosters innovation by ensuring that patents do not impede future research and development. When invalid patents are challenged, it paves the way for others to build upon existing knowledge and create new, innovative treatments. This promotes a more dynamic and competitive pharmaceutical industry, leading to the development of new medicines and improved healthcare options...” – Generation Patient (A young adult patient led organization that increases the health literacy, confidence, self-management skills, public policy knowledge, and advocacy strategies of young adult patients)

The Proposals Will Drive-up Costs and Hurt the Economy

The specific points of opposition in individual comments vary, but in many cases the overarching sentiment is consistent. Restricting access to the PTAB, as proposed in the ANPRM and PREVAIL Act, will increase costs and directly harm productive participants in the economy. Congress intended for the PTAB to be an open, more efficient alternative to costly litigation and settlements. Rolling back access will be a drag on the economy and a burden for businesses, small and large. 

Business and labor groups, and patent policy experts, submitted comments emphasizing the economic damage and higher costs that the changes to PTAB review would catalyze:

  • “...The proposed changes could have a considerable impact on our economy and the ability of businesses to defend themselves against attacks from patent trolls. 

    Our members are on the forefront of the construction and energy industries in New Hampshire, and around the country. But at a time when the construction industry is only beginning to rebound from the events of 2020, companies are under threat from non-practicing entities. Instead of investing in wages and jobs, companies are spending thousands of dollars settling frivolous lawsuits out of court. These problems will only get worse under the recently proposed rules. 

    A diverse range of industries rely on the Patent Trials and Appeal Board (PTAB) review process as a means to combat low-quality patents, and protect themselves from patent trolls by targeting the bad patents these companies use to go after main street businesses. Unfortunately, the USPTO’s Advanced Notice of Proposed Rulemaking (ANPRM) published on April 20 is poised to undermine this effective instrument by making it harder for businesses to use the Inter Partes Review (IPR) process to defend themselves from unfounded patent lawsuits. Doing so will force businesses to endure costly and prolonged court litigation, draining their limited resources – and putting jobs at risk.” - D. Spechuilli, Laborers Local 976 (Laborers’ International Union chapter based out of Portsmouth, New Hampshire)

  • “Our association is made up of over 1,100 businesses across the South Placer region, including restaurants, retailers, realtors, hospitality and event services, finance and insurance companies, and more. Our members rely on the Patent Trials and Appeal Board (PTAB)’s review process to invalidate patents that never should have been issued in the first place. The recently proposed rules would significantly curtail companies’ abilities to seek PTAB review in many cases when they are sued on invalid patents. Rather than being able to rely on the Inter Partes Review (IPR) system to invalidate bad patents, companies will be forced to go to litigation – spending valuable time and money on expensive lawsuits…

    …With these proposed rules, the USPTO will make it much harder to institute an IPR, and will hurt American businesses and consumers. The changes the ANPRM proposes include shortening the filing deadline for an IPR from the deadline created by the AIA, raising the standard for instituting a review, and even changing who is allowed to file an IPR.

    Businesses relies on the PTAB and the IPR process to help protect them from the high costs associated with frivolous patent litigation. We ask that you reconsider the proposed rules.” – R. Ghadban, Roseville Area Chamber of Commerce (An association made up of over 1,100 businesses across the South Placer region in California)

  • “I strongly oppose any effort to limit the sorts of patents that can be challenged via IPR. The IPR process has proven to work extraordinarily well. It has lowered the cost of resolving the validity of disputed patents by an order of magnitude, without changing the statistics about who wins validity disputes.

    That is a good thing for everyone involved in the system, with one exception: patent trolls who depend on the high cost of litigation to leverage their settlements. Exempting small entities (which includes many large patent litigation farms, in part because of fraudulent concealment of ownership) will eliminate the lowest cost mechanism of resolving patent validity. True small patent owners should welcome a 90% reduction in costs. Only companies whose business model depends on high cost and uncertainty tend to oppose it.” – M. Lemley, William H. Neukom Professor, Stanford Law School (Director, Stanford Program in Law, Science, and Technology)


* Analysis applies to comments that were posted on regulations.gov by August 22, 2023. Comments that were critical of non-practicing entities (NPEs) or patent trolls were categorized as opposing the proposed rules. Taken as a whole, the ANPRM’s provisions would restrict access to Patent Trial and Appeal Board review and make it more difficult to petition for review of patents held by NPEs.